CD8A and neoplasm: Accordingly, the E7 antigen, just like the prostate specific antigen [7], induced weak CD8 T-cell responses and poor protection when expressed within full length proteins in recombinant MCMVs, but a single E7 peptide fused to the C-terminus of the ie2 MCMV protein induced not only robust CD8 T-cell responses, but also absolute anti-tumor immunity (Fig 1).